1. Home
  2. SPRO vs MNSB Comparison

SPRO vs MNSB Comparison

Compare SPRO & MNSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.59

Market Cap

124.5M

Sector

Health Care

ML Signal

HOLD

Logo MainStreet Bancshares Inc.

MNSB

MainStreet Bancshares Inc.

HOLD

Current Price

$21.80

Market Cap

166.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
MNSB
Founded
2013
2003
Country
United States
United States
Employees
N/A
204
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
124.5M
166.4M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SPRO
MNSB
Price
$2.59
$21.80
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
263.5K
57.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
1.84%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$47,977,000.00
N/A
Revenue This Year
N/A
$1.50
Revenue Next Year
N/A
$3.77
P/E Ratio
N/A
$12.64
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$15.00
52 Week High
$3.09
$23.44

Technical Indicators

Market Signals
Indicator
SPRO
MNSB
Relative Strength Index (RSI) 69.68 46.88
Support Level $2.15 $20.88
Resistance Level $2.70 $22.13
Average True Range (ATR) 0.10 0.58
MACD 0.04 -0.13
Stochastic Oscillator 81.36 38.86

Price Performance

Historical Comparison
SPRO
MNSB

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About MNSB MainStreet Bancshares Inc.

MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.

Share on Social Networks: